NexMed claimed that the incorporation of NexAct enabled the dose of A6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.
Bassam Damaj, president and CEO of NexMed, said: “These new findings, incorporating the NexAct-A6 peptide formulation, correlate with the half life and delivery profile of the A6 compound from Angstrom’s previous studies using the higher dose.
“The positive results offer Angstrom the potential to clinically test the NexAct-A6 peptide at much higher doses while maintaining continuous coverage of the intended therapeutic target in human patients.
“This study was NexMed’s first entry into the subcutaneous delivery of peptide drugs, and the results further confirmed the depot-like effect of the NexAct technology which we had seen in our subcutaneous delivery studies with insulin and taxol.”
Malcolm Finlayson, president and CEO of Angstrom Pharmaceuticals, said: “Our relationship with NexMed continues to evolve in a fast and promising way. This new data is very exciting and warrants further investigation to support the opportunity to license the NexAct technology for human clinical trials.”